In a real-world target trial emulation of 161,798 matched obese adults without diabetes, GLP-1 receptor agonist use was tied to a 41% lower risk of obesity-associated malignant neoplasm vs diet or exercise counselling alone over a median 2 years (HR 0.59, 95% CI 0.53-0.67). Published in Annals of Oncology, the study also found nearly 70% lower risk in men and a 58% reduction in endometrial cancer incidence, though this benefit was not observed among Black patients.

Why It Matters To Your Practice

• GLP-1 RAs may offer an added preventive benefit for obese, non-diabetic adults already being considered for treatment.

• The analysis evaluated 13 obesity-associated cancers using TriNetX real-world data from U.S. health records.

• Findings may help support shared decision-making when discussing obesity treatment options beyond weight loss alone.

Clinical Benefits

• Overall risk of obesity-associated cancer was 41% lower with GLP-1 RA therapy than with lifestyle counselling alone.

• Subgroup findings suggested larger benefit in men, with risk reduced by nearly 70%.

• Among gynecologic cancers, endometrial cancer incidence was reduced by 58%.

Managing Risks

• This was an observational target trial emulation, so the findings do not prove causation.

• Median follow-up was only 2 years, limiting conclusions about long-term cancer prevention.

• No reduction was observed among Black patients, underscoring the need to consider access, baseline risk, and possible biologic differences.

The Bottom Line

• For eligible obese adults without diabetes, possible cancer-risk reduction may be a useful secondary consideration when weighing GLP-1 RA therapy.

• Malignant neoplasm prevention should not be a stand-alone reason to prescribe these agents at this time.

• Use these data to inform, not replace, individualized counseling on benefits, costs, adverse effects, and follow-up.